CN113287754A

CN113287754A - Food composition for resisting helicobacter pylori

Info

Publication number: CN113287754A
Application number: CN202110579159.3A
Authority: CN
Inventors: 白云昇; 谢瑶; 路子佳
Original assignee: BEIJING DAWN AEROSPACE BIO-TECH CO LTD
Current assignee: BEIJING DAWN AEROSPACE BIO-TECH CO LTD
Priority date: 2021-05-26
Filing date: 2021-05-26
Publication date: 2021-08-24

Abstract

The invention provides a food composition for resisting helicobacter pylori, which comprises the following components: main materials and auxiliary materials; the main material comprises lactobacillus johnsonii LJ88, fermented soybean protein powder, inulin, erythritol and xylitol; the weight percentage of the main material is 98-99%, and the weight percentage of the auxiliary material is 1% -2%. The composition adopts the inactivated bacteria of lactobacillus johnsonii, can effectively inhibit the helicobacter pylori from being colonized in a human body, can also play the role of prebiotics, is matched with the fermented soybean protein powder, inulin, erythritol and xylitol to supplement each other, not only improves the effect of preventing and assisting in treating the helicobacter pylori infection in the prior art, but also plays a role in improving the environment and the health state of the stomach, has simple components, low cost and easy industrialization, and greatly reduces the treatment and prevention cost for preventing and assisting in treating the helicobacter pylori infection.

Description

Food composition for resisting helicobacter pylori

Technical Field

The invention relates to the technical field of stomach health care, in particular to a food composition for resisting helicobacter pylori.

Background

Helicobacter pylori (Hp) is a unipolar, multifilamentary, blunt-ended, helically-curved gram-negative rod that colonizes the human gastric mucosal epithelium.

According to the statistics of the world health organization in 2002, Hp infection is the third most infectious disease next to AIDS and tuberculosis, and about half of people worldwide have Hp infection or infection history. At present, the helicobacter pylori infection rate in China is about 40-60%. According to the relevant data in the 'Chinese helicobacter pylori infection epidemiology Meta analysis', 66 Hp epidemiology infection rate surveys from 1990 to 2002 relate to 22 provinces, 55 regions and 25209 cumulative detection people, the Hp infection rate is 34.52-80.55%, the infection rate of most regions is more than 50%, and the average infection rate is 58.07%

The fifth national consensus report on helicobacter pylori infection treatment (2017) indicated that Hp is the most important controllable risk factor for the prevention of gastric cancer. More than 90% of patients with duodenal bulbar ulcer, 60% -80% of patients with gastric ulcer and gastritis, and more than 80% of patients with gastric cancer are all associated with Hp infection. The medicine can be used for treating Hp, reducing the occurrence of 37% gastric cancer of people, and effectively preventing and treating the gastric cancer of people without precancerous lesions.

The degree of the pathological changes caused by H.pylori varies depending on individual patients. Some patients may present with only gastritis or no apparent gastric lesions after infection, while some may present with peptic ulcers, gastritis verrucosa, atrophic gastritis and even gastric cancer.

Once infected with Hp, it is not only difficult to cure itself but also easy to recur. The results of domestic investigation and research on nearly 5 ten thousand subjects show that the Hp infection is related to the living environment, living conditions, dining environment, working strength, smoking and drinking, exercise strength and the like, and has obvious family aggregation. Smoking, drinking and long-term overtime are all high risk factors. At present, the treatment method aiming at helicobacter pylori mainly takes drug therapy as main treatment, but drug resistance and drug side effects are generated in the drug therapy, so that the development of functional food products with the functions of resisting helicobacter pylori and improving stomach health for daily prevention and adjuvant treatment of helicobacter pylori infection has important significance.

Disclosure of Invention

The invention provides a food composition for resisting helicobacter pylori, which can be used for preventing and assisting in treating helicobacter pylori infection at low cost and improving the environment and health state of the stomach.

In order to achieve the purpose, the invention adopts the following technical scheme.

A food composition for anti-helicobacter pylori comprising: main materials and auxiliary materials;

the main material comprises lactobacillus johnsonii LJ88, fermented soybean protein powder, inulin, erythritol and xylitol;

the weight percentage of the main material is 98-99%, and the weight percentage of the auxiliary material is 1% -2%.

Preferably, the weight percentage of the lactobacillus johnsonii LJ88 is 3-8%, the weight percentage of the fermented soybean protein powder is 25-35%, the weight percentage of the inulin is 25-27%, the weight percentage of the erythritol is 25-35%, and the weight percentage of the xylitol is 5-10%.

Preferably, the auxiliary material is 1.25 percent of the essence for food in percentage by weight.

Preferably, the weight percentage of the lactobacillus johnsonii LJ88 is 5.00%, the weight percentage of the fermented soybean protein powder is 30.00%, the weight percentage of the inulin is 26.25%, the weight percentage of the erythritol is 30.00%, and the weight percentage of the xylitol is 7.50%.

Preferably, the lactobacillus johnsonii LJ88 is inactivated bacteria.

The composition has the effects of resisting helicobacter pylori, improving the health of the stomach and reducing the incidence rate of diseases for adjuvant therapy of helicobacter pylori infection, is suitable for common people and people with the history of infecting helicobacter pylori, and has the following synergistic effect among the effects of the components:

lactobacillus johnsonii LJ88 is found in human gastric juice, has strong tolerance to acid, and can deform pathogenic bacteria such as helicobacter pylori (such as spiral disappearance, cell body bending, spheroid formation and the like) so as to inhibit proliferation of the pathogenic bacteria, act on stomach wall, inhibit production of gastrin, inhibit secretion of gastric acid, and relieve symptoms such as stomach ache, heartburn, acid regurgitation, flatulence and the like.

The selected Lactobacillus johnsonii is a killed bacterium, and the killed bacterium not only can effectively inhibit the helicobacter pylori from being colonized in a human body, but also can play the role of prebiotics, namely the lactobacillus johnsonii becomes food of intestinal beneficial bacteria and has the function of adjusting the intestinal environment. In addition, the use of the Lactobacillus johnsonii inactivated bacteria reduces the requirements on transportation and storage conditions in the production method in the prior art, has low cost, and greatly reduces the treatment and prevention cost for preventing and assisting in treating helicobacter pylori infection.

Fermenting soybean protein powder: is prepared from soybean and nutrients through mixing, fermenting by lactobacillus delbrueckii, pasteurizing and spray drying. The soybean protein powder prepared by fermentation is rich in nutritional factors (such as natural components of soybeans, various peptides and microbial metabolites obtained by fermentation, lactobacillus delbrueckii and the like), can solve the negative effects brought by the anti-nutritional factors, can reduce gastric acid transiently, and can relieve symptoms of stomach burning, nausea and the like quickly. In addition, the nutritional factors rich in the fermented soybean protein powder can help the recovery of gastric mucosa, reduce inflammation and promote immune response.

Inulin has been approved by China as a new food raw material (original new resource food) in 2009, and is obtained by using chicory root and Jerusalem artichoke as raw materials, removing protein and minerals, and performing spray drying and other steps, wherein the inulin (a mixture of fructose polymers, the polymerization degree range of 2-60) > 86.0%, and other saccharides (glucose + fructose + sucrose) < 14.0%. Inulin is a natural water-soluble dietary fiber, can hardly be decomposed and digested by gastric acid, and can be utilized by beneficial microorganisms only in colon to improve intestinal environment. In addition, inulin has positive improving effect on cardiovascular diseases, obesity, diabetes, immunity, etc.

Erythritol is a zero-calorie sugar alcohol, 80% of erythritol enters human blood after being eaten by a human body, but is not degraded by enzyme, can be discharged from the blood to urine only through kidneys (easy to be absorbed by small intestines), does not participate in sugar metabolism and blood sugar change, and is suitable for diabetics to eat. It is not fermented in colon, and can avoid gastrointestinal discomfort. In addition, the sweetness of the erythritol is only 60% -70% of that of the sucrose, and the erythritol has cool taste, pure taste and no aftertaste, and can cover other odors and improve the flavor of the beverage.

Xylitol is an intermediate of carbohydrate metabolism of a human body, under the condition that insulin is lack in the body to influence the carbohydrate metabolism, insulin is not needed to promote, the xylitol can also permeate cell membranes to be absorbed and utilized by tissues, the synthesis of hepatic glycogen is promoted to supply nutrition and energy to cells, the blood sugar value cannot be increased, and the xylitol is a nutritional sugar substitute suitable for people with abnormal blood sugar. In addition, erythritol and xylitol can prevent and protect dental caries and inhibit oral bacteria.

According to the technical scheme provided by the food composition for resisting helicobacter pylori, the composition provided by the invention adopts the inactivated bacteria of lactobacillus johnsonii, so that the helicobacter pylori can be effectively inhibited from being colonized in a human body, the prebiotics effect can be exerted, and the composition is matched with the fermented soybean protein powder, inulin and other components to supplement each other, so that the composition has the effects of well preventing and assisting in treating helicobacter pylori infection and improving the environment and the health state of the stomach, is simple in component, low in cost and easy to industrialize, and greatly reduces the treatment and prevention cost for preventing and assisting in treating helicobacter pylori infection.

Additional aspects and advantages of the invention will be set forth in part in the description which follows, and in part will be obvious from the description, or may be learned by practice of the invention.

Drawings

In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings needed to be used in the description of the embodiments are briefly introduced below, and it is obvious that the drawings in the following description are only some embodiments of the present invention, and it is obvious for those skilled in the art to obtain other drawings based on these drawings without creative efforts.

FIG. 1 is a typical graph of the effect of test samples on H.pylori in the gastrointestinal tract of zebrafish after treatment;

FIG. 2 is a graph of fluorescence intensity of the gastrointestinal tract of zebra fish after treatment of test samples;

FIG. 3 is a graphical representation of the effect on gastrointestinal tract tissue structure using the compositions of this example.

Detailed Description

Reference will now be made in detail to embodiments of the present invention, examples of which are illustrated in the accompanying drawings, wherein like reference numerals refer to the same or similar elements or elements having the same or similar function throughout. The embodiments described below with reference to the accompanying drawings are illustrative only for the purpose of explaining the present invention, and are not to be construed as limiting the present invention.

As used herein, the singular forms "a", "an", "the" and "the" are intended to include the plural forms as well, unless the context clearly indicates otherwise. It will be further understood that the terms "comprises" and/or "comprising," when used in this specification, specify the presence of stated features, integers, steps, operations, elements, and/or components, but do not preclude the presence or addition of one or more other features, integers, steps, operations, elements, components, and/or groups thereof. It will be understood that when an element is referred to as being "connected" or "coupled" to another element, it can be directly connected or coupled to the other element or intervening elements may also be present. Further, "connected" or "coupled" as used herein may include wirelessly connected or coupled. As used herein, the term "and/or" includes any and all combinations of one or more of the associated listed items.

It will be understood by those skilled in the art that, unless otherwise defined, all terms (including technical and scientific terms) used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. It will be further understood that terms, such as those defined in commonly used dictionaries, should be interpreted as having a meaning that is consistent with their meaning in the context of the prior art and will not be interpreted in an idealized or overly formal sense unless expressly so defined herein.

For the convenience of understanding the embodiments of the present invention, the following description will be further explained by taking several specific embodiments as examples in conjunction with the drawings, and the embodiments are not to be construed as limiting the embodiments of the present invention.

Example one

The present embodiment provides a food composition for anti-helicobacter pylori, comprising: main materials and auxiliary materials; the main material comprises lactobacillus johnsonii LJ88, fermented soybean protein powder, inulin, erythritol and xylitol; the weight percentage of the main material is 98-99%, and the weight percentage of the auxiliary material is 1% -2%. Specifically, the weight percentage of the main material is 98%, and the weight percentage of the auxiliary material is 2%. Lactobacillus johnsonii LJ88 is a killed bacterium.

The respective component ratios are shown in table 1 below:

TABLE 1

Name (R)	Addition amount/mg	Mass percent
			Lactobacillus johnsonii	60	3％
Fermented soybean protein powder	600	30％
			Inulin powder	500	25％
Erythritol and its preparation method	700	35％
			Xylitol, its preparation method and use	100	5％
Edible essence	40	2％
			Totaling:	2000	100％

example two

The present embodiment provides a food composition for anti-helicobacter pylori, comprising: main materials and auxiliary materials; the main material comprises lactobacillus johnsonii LJ88, fermented soybean protein powder, inulin, erythritol and xylitol; the weight percentage of the main material is 98-99%, and the weight percentage of the auxiliary material is 1% -2%. Specifically, the main material accounts for 99% by weight, and the auxiliary material accounts for 1% by weight. Lactobacillus johnsonii LJ88 is a killed bacterium.

The respective component ratios are shown in table 2 below:

TABLE 2

EXAMPLE III

The respective component ratios are shown in table 3 below, for example:

TABLE 3

Name (R)	Addition amount/mg	Mass percent
			Lactobacillus johnsonii	60	3％
Fermented soybean protein powder	700	35％
			Inulin powder	500	25％
Erythritol and its preparation method	500	25％
			Xylitol, its preparation method and use	200	10％
Edible essence	40	2％
			Totaling:	2000	100％

example four

The present embodiment provides a food composition for anti-helicobacter pylori, comprising: main materials and auxiliary materials; the main material comprises lactobacillus johnsonii LJ88, fermented soybean protein powder, inulin, erythritol and xylitol; the weight percentage of the main material is 98.75 percent, and the weight percentage of the auxiliary material is 1.25 percent. Specifically, the weight percentage of the main material is 98%, and the weight percentage of the auxiliary material is 2%. Lactobacillus johnsonii LJ88 is a killed bacterium.

The respective component ratios are shown in table 4 below, for example:

TABLE 4

Firstly, the composition of this example was used to test zebrafish as follows:

the zebra fishes are all raised in fish-raising water with the temperature of 28 ℃ (the water quality is that 200mg of instant sea salt is added into every 1L of reverse osmosis water, the conductivity is 450-: SYXK (Zhe) 2012-0171, and the feeding management meets the requirements of the international AAALAC certification (certification number: 001458). Wild type AB strain zebra fish is adopted and carried out in a natural pairing mating propagation mode, the total number of 600 tails is 30 tails per experimental group, and the age is 4 days after fertilization (4 dpf).

1) Evaluation of inhibitory efficacy against helicobacter pylori

180-tailed 4dpf wild-type AB strain zebrafish were randomly selected in 6-well plates, and 30 zebrafish were treated per well (experimental group). The sample groups were each subjected to water dissolution at a concentration of 125. mu.g/mL in test group 1, test group 2, test group 3 and test group 4, while the positive control group contained clarithromycin at a concentration of 125. mu.g/mL and the model control group contained 3mL per well. After 18 hours of treatment at 28 ℃ in each experimental group, zebrafish were infected with 1.4X 108CFU/mL of H.pylori, and the experiment was terminated after 3 hours of continued co-treatment with H.pylori. 8 zebra fish are randomly taken from each experimental group, photographed under a fluorescence microscope and stored, image analysis is carried out by NIS-Elements D3.10 advanced image processing software, data are collected, gastrointestinal fluorescence intensity (S) of the zebra fish is analyzed, and the inhibition effect of the composition on helicobacter pylori is evaluated according to the statistical result of the gastrointestinal fluorescence intensity. Statistical treatment results are expressed as mean ± SE.

Statistical analysis was performed using SPSS software, with p <0.05 indicating significant differences and p <0.01 indicating very significant differences.

FIG. 1 is a typical view of the gastrointestinal tract of zebra fish treated by a test sample, FIG. 2 is a fluorescence intensity view of the gastrointestinal tract of zebra fish treated by the test sample, and it can be seen from FIGS. 1 and 2 that the test sample composition has a significant inhibitory effect on helicobacter pylori.

2) Influence on gastrointestinal tract tissue structure

Randomly selecting 210 tail 4dpf wild type AB strain zebra fish in a 6-hole plate, and treating 30 tail zebra fish in each hole. The sample groups were each dissolved in water to give a concentration of 125. mu.g/mL in example 1, example 2, example 3 and example 4, and the positive control group was clarithromycin at a concentration of 125. mu.g/mL, while the normal control group and the model control group were set to have a volume of 3mL per well. After 18 hours of treatment, 1.4X 10 of the total amount of the test groups except the normal control group were used⁸CFU/mL helicobacter pylori infected zebrafish continued co-treatment with helicobacter pylori for 3 hours after which the experiment was ended. Immediately fixing the zebra fish of each experimental group by using 4% of tissue cell fixing solution at the experimental end, and performing histopathological analysis on the gastrointestinal tract of the zebra fish after the steps of serial dehydration, embedding, slicing, dyeing, sealing and the like.

FIG. 3 is a typical graph showing the effect of the composition of this example on the gastrointestinal tract tissue structure, and referring to FIG. 3, the normal control group zebra fish gastrointestinal tract has a large number of folds and is clearly characterized by the close connection of intestinal epithelial cells with cilia and mucosa. The number of folds in the gastrointestinal tract of the zebra fish in the model control group (helicobacter pylori treatment group) is reduced, and the gastrointestinal cavity is obviously reduced. The positive control group clarithromycin group zebra fish has obvious recovery of gastrointestinal cavity shrinkage and certain recovery of gastrointestinal tract folds. The shrinkage of the gastrointestinal cavity of the zebra fish in each composition sample group is obviously recovered, the number of intestinal folds and the gastrointestinal tract tissue cell morphology are similar to those of a normal control group, and the state is better than that of a positive control group.

Second, the following is a typical case test of applying the food composition obtained in this example to patients or persons with stomach discomfort:

patients of 1 year and 35 years old suffer from gastritis 1 time a day and 2g a day, after 3 days of use, the original symptoms such as nausea, stomachache, stomach burning pain, inappetence and the like are obviously relieved, and the patients are basically cured after 4 weeks.

Patients 2, male, 38 years old and Hp positive gastric ulcer patients are treated by a four-combination therapy, and have relapsed for 2 times, 2 times a day and 2g a day, after the patients are used for 3 days, symptoms such as nausea, stomachache, flatulence and the like are obviously relieved, and the HP result is rechecked to be negative after the patients are used for 15 days.

Patients 3, male, 31 years old, Hp positive gastritis patients, 2 times a day, 2g a day, after using for 3 days, the related symptoms such as acid regurgitation and heartburn are obviously relieved, and after using for 15 days, the HP result is rechecked to be negative.

In conclusion, the food composition obtained in the embodiment has a good effect on resisting helicobacter pylori, has the effect of improving the stomach health, is simpler in composition, is easy to industrialize and greatly reduces the production cost.

The above description is only for the preferred embodiment of the present invention, but the scope of the present invention is not limited thereto, and any changes or substitutions that can be easily conceived by those skilled in the art within the technical scope of the present invention are included in the scope of the present invention. Therefore, the protection scope of the present invention shall be subject to the protection scope of the claims.

Claims

1. A food composition for combating helicobacter pylori comprising: main materials and auxiliary materials;

2. The composition of claim 1, wherein the lactobacillus johnsonii LJ88 is present in an amount of 3 to 8 wt%, the fermented soy protein flour is present in an amount of 25 to 35 wt%, the inulin is present in an amount of 25 to 27 wt%, the erythritol is present in an amount of 25 to 35 wt%, and the xylitol is present in an amount of 5 to 10 wt%.

3. The composition as claimed in claim 1, wherein the adjuvant is 1.25% by weight of essence for food.

4. The composition of claim 2, wherein the lactobacillus johnsonii LJ88 is present in an amount of 5.00 wt%, the fermented soy protein flour is present in an amount of 30.00 wt%, the inulin is present in an amount of 26.25 wt%, the erythritol is present in an amount of 30.00 wt%, and the xylitol is present in an amount of 7.50 wt%.

5. The composition of claim 1, wherein said lactobacillus johnsonii LJ88 is a killed bacterium.